ACRV vs CRL · $65.1M cap vs rev $2.00B
Acrivon Therapeutics, Inc. Common Stock (ACRV) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
Acrivon Therapeutics, Inc. Common Stock (ACRV) is a biotechnology company listed on NASDAQ.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
ACRV does not have a complete income-statement cache yet.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
ACRV currently screens at market cap $65.1M. CRL currently screens at market cap $7.78B.
Not investment advice. Open the ACRV and CRL stock pages for the full models.
Not investment advice.